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Edited by Maurice MontalAbstract The CaVa2d auxiliary subunit is a glycosylated
protein that regulates the traﬃcking and function of voltage-
gated Ca2þ channels. One of the most prominent roles of CaVa2d
is to increase whole-cell Ca2þ current amplitude. Using N-
glycosidase F and truncated forms of CaVa2d, earlier studies
suggested an important role for N-linked glycosylation in current
stimulation. Here, we used site-directed mutagenesis and heter-
ologous expression in HEK-293 cells to examine the impact of
individual glycosylation sites within the CaVa2d subunit on the
regulation of Ba2þ currents through recombinant Ca2þ channels.
We found two N-glycosylation consensus sites (NX(S/T)) in the
extracellular a2 domain of the protein that are functional.
Substitution of asparagines for glutamines at amino acid
positions 136 and 184 rendered these sites non-functional as
shown by patch-clamp experiments. These results corroborate
that N-glycosylation is required for the CaVa2d subunit-induced
current stimulation and suggest that sites N136 and N184 are
directly involved in this action. Likewise, N136Q and N184Q
mutations prevented whole-cell current stimulation without
altering its kinetic properties, suggesting a regulation on the
number of functional channels at the plasma membrane.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Voltage-gated Ca2þ (CaV) channels are membrane-spanning
proteins that mediate Ca2þ entry into all excitable and many
non-excitable cells, thereby initiating a number of important
cellular processes including gene transcription, muscle con-
traction, and neurotransmitter release. CaV channels are
functionally diverse and ﬁve diﬀerent types have thus far been
deﬁned: T, L, N, P/Q and R [1]. These channel types can be
separated into two classes based on threshold of voltage acti-
vation: low voltage- and high voltage-activated channels (LVA
and HVA, respectively). HVA channels are oligomeric com-
plexes consisting of one pore-forming (a1) subunit and three
auxiliary subunits: a2d, b, and c [2,3]. According to molecular
studies, the CaV2.2 (formerly a1B) subunit originate the N-type* Corresponding author. Fax: +52-55-5061-3754.
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tion is essential in excitation–secretion coupling [2,4]. Expres-
sion of multiple CaV2.2 splice variants [5,6] and association
with auxiliary subunits [7,8] determine the diversity of N-type
Ca2þ currents in the nervous system.
The auxiliary CaVa2d subunit is a transmembrane protein
that can be encoded by four diﬀerent genes with multiple splice
variants possible for each gene [9]. The CaVa2d protein is post-
translationally cleaved into a long, N-terminal, extracellular a2
polypeptide and a shorter, membrane-anchored d protein,
which remain covalently linked by disulﬁde bonds [10,11]. The
ultimate functional properties of the CaV channel complex can
be ﬁnely tuned by the presence of CaVa2d [9,12]. Upon re-
combinant co-expression, CaVa2d regulate channel activity by
enhancing the whole-cell current density [13–19]; as well as by
shifting the voltage dependence of activation to more negative
potentials [19,20], and/or increasing the steady-state inactiva-
tion of the ionic [17,20] and gating [21] currents. In addition,
CaVa2d possess binding sites for the antiepileptic drug gaba-
pentin [22–24], which exerts acute [25–27] and chronic inhibi-
tory actions on CaV channel functional expression [28,29].
Lastly, the mouse mutants ducky, ducky2J [30–32] and entla
[33] are shown to be functional CaVa2d null alleles. Homozy-
gote animals exhibit decreased CaV currents in cerebellar
neurons and develop ataxia, absence epilepsy and paroxysmal
dyskinesia [33,34].
Experimental evidence suggests that one of the most promi-
nent and potentially important roles of the CaVa2d subunit is to
enhance Ca2þ current amplitude [9,12]. However, the deter-
minants in CaVa2d responsible for the up-regulation in channel
activity have not been clearly identiﬁed or separated, though
this process has been attributed to glycosylation. It has been
demonstrated that deglycosylation with PNGase F of intact
Xenopus oocytes expressing recombinant CaV2.1/b4/a2d-1
channels resulted in a signiﬁcant reduction of macroscopic
current amplitude [16]. In contrast, identical treatment of oo-
cytes expressing only CaV2.1/b4 subunits did not have an eﬀect
on current amplitude [16]. Likewise, N-terminal truncations of
CaVa2d resulted in reductions in current amplitude through
CaV2.1/b4/a2d-1 channels expressed in oocytes, presumably by
a gradual deletion of potential N -glycosylation sites [16]. The
smallest N-terminal truncation tested (ND28–184) completely
abolished the functional activity of the CaVa2d-1 subunit [16].
However, to date there has been no systematic approach to-
ward delineating the structural determinants that are respon-
sible for the eﬀects mediated by CaVa2d. In the current report,ation of European Biochemical Societies.
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(N136 and N184) that are critical for the CaVa2d subunit-
mediated regulation of neuronal CaV channels.2. Materials and methods
2.1. Site-directed mutagenesis
The cDNA coding the CaVa2d-1 was subcloned into the SacII and
EcoRI sites of pIRES-hrGFP-1a vector (Stratagene). The vector con-
tains a CMV promotor, a multiple cloning site, followed by an internal
ribosomal entry site (IRES) from encephalomyocarditis virus, then the
gene encoding the Green Fluorescent Protein (GFP) and poly A region
(SV40). N! Q mutations at two amino acid residues from the N-
terminus (at positions 136 and 184) of the CaVa2d-1 subunit were in-
troduced to prevent N -linked glycosylation. These point mutations
were introduced with 40-mer synthetic oligonucleotides using the
Quick-Change XL-mutagenesis kit (Stratagene). cDNAs of the mutant
channel subunits were sequenced in both directions on an automated
sequencer (ABIPrism310, Perkin–Elmer Applied Biosystems).
2.2. SDS–PAGE and immunoblot analysis
Microsomes from transfected HEK-293 cells were prepared as
previously described [17,38]. Samples were subjected to gel electro-
phoresis under reducing conditions using 2.5% (v/v) b-mercap-
toethanol. All samples were heated at 90 C for 5 min and 200 lg of
protein/slot were loaded on 5% polyacrylamide gels. For Western blot
analysis, proteins were blotted onto nitrocellulose membranes and
blots were developed as described [17,38] with speciﬁc polyclonal
primary antibodies (Rabbit 136) [16] used in a 1:4000 dilution. Rabbit
136 antibody recognizes a 17 amino acid sequence (residues 839–856)
of the rat a2d-1 subunit. The speciﬁc protein bands were detected
using the ECL detection method according to the manufacturers’
instructions.
2.3. Cell culture and recombinant CaV2.2 channel expression
Human embryonic kidney (HEK-293) cells were grown in DMEM-
high glucose supplemented with 10% equine serum, 2 mM L-gluta-
mine, 110 mg/l sodium pyruvate and 50 lg/ml gentamycin, at 37 C in
a 5% CO2–95% air humidiﬁed atmosphere. After splitting the previous
day and seeding at 60% conﬂuency, cells were transfected using the
Lipofectamine Plus reagent (Gibco BRL) with 1.2 lg plasmid cDNA
encoding the rabbit brain N-type Ca2þ channel CaV2.2 pore-forming
subunit (formerly a1B; GenBank accession number D14157) [35] in
combination with 1.2 lg cDNA of the rat brain CaVb3 (M88751) [36],
and 1.2 lg cDNA coding the rat brain CaVa2d-1 (M86621) [37] or its
mutants.
2.4. Electrophysiology
Forty eight hours after transfection, cells expressing the GFP reporter
gene were subjected to the whole-cell mode of the patch clamp tech-
nique [39]. Brieﬂy, currents were recorded with an Axopatch 200B
ampliﬁer (Axon Instruments) and acquired on line using a Digidata
1320A interface with pClamp8 software (Axon Instruments). After es-
tablishing the whole-cell mode, capacitive transients were canceled with
the ampliﬁer. Currents were obtained from a holding potential (HP) of
)80 mV applying test pulses every 20 s. Leak and residual capacitance
currents were subtracted on-line by a P/4 protocol. Current signals were
ﬁltered at 2 kHz (internal 4 pole Bessel ﬁlter) and digitized at 5.71 kHz.
Membrane capacitance (Cm) was determined as described previously
[40] and used to normalize currents. The bath recording solution con-
tained (in mM) 10 BaCl2, 125 TEA-Cl, 10 HEPES and 15 glucose (pH
7.3). The internal solution consisted of (in mM) 110 CsCl, 5 MgCl2, 10
EGTA, 10 HEPES, 4 Na-ATP and 0.1 GTP (pH 7.3). Experiments were
performed at room temperature (25 C).
2.5. Data analysis
The data are given as meansS.E. Statistical diﬀerences between two
means were determined by Student’s t tests (P < 0:05). Current activa-
tion and decay were ﬁtted with single exponential equations of the form:
A expðt=sÞ þ c, where A is the initial amplitude (pA), t is time (ms), s
is the time constant and c is a constant. Steady-state inactivation
curves were ﬁtted with a Boltzmann function: IBa ¼ Imax=ð1þexp½ðVm  V1=2Þ=kÞ, where the current amplitude IBa has decreased to a
half-amplitude at V1=2 with an e-fold change over k mV.3. Results
We ﬁrst searched for potential glycosylation consensus sites
(NX(S/T)) in the sequence of the rat brain CaVa2d-1 subunit.
By using the NetNGlyc1.0 software [41] (available at the URL
http://www.cbs.dtu.dk/services/NetNGlyc/), we detected 10
putative N-linked glycosylation sites in the extracellular a2
domain. Interestingly, two of them were present in the 28–184
stretch (Fig. 1A). Next, to test whether these sites were post-
translationally modiﬁed and whether such modiﬁcations
would entail any functional consequences, we created two
single and one double N -glycosylation mutants (N136Q and/or
N184Q). All cDNA constructs were analyzed by XhoI diges-
tion (Fig. 1B) and sequenced to conﬁrm the desired mutations.
The wild-type CaVa2d-1 and its three mutated versions were
expressed in HEK-293 cells and analyzed by immunoblotting.
As shown in Fig. 1C, when membranes of wild-type CaVa2d-1
expressing cells were resolved by SDS–PAGE and probed with
a polyclonal anti-a2 antibody, a speciﬁc band of 130 kDa
was detected. In contrast, Western blot of the CaVa2d-1 single
glycosylation mutants showed shifts in the mobility of the
130 kDa protein to 126 kDa on a 5% gel, suggesting im-
paired N -glycosylation of sites N136 and N184. In addition,
evidence of a lower molecular weight protein corresponding to
the unglycosylated CaVa2d-1 double mutant (DM) was also
obtained. These results strongly suggest that sites N136 and
N184 are glycosylated in vivo.
In order to evaluate the functional role of N -linked carbo-
hydrate modiﬁcation of the CaVa2d-1 subunit, the whole-cell
patch clamp technique was used to study the macroscopic
Ba2þ currents (IBa) through recombinant CaV channels
(CaV2.2/b3) in HEK-293 cells transiently expressing wild-type
CaVa2d-1 and its mutants. Fig. 2A shows representative cur-
rent traces recorded during depolarizing voltage steps to +10
mV from a HP of )80 mV. Control experiments carried out
using cells transfected with the wild-type CaVa2d-1 showed
that the current levels ranged up to )2.8 nA, with an average
peak current of )782 96 pA (Fig. 2B). Recordings performed
in cells transfected with the single mutations (N136Q and
N184Q) indicated that the stimulatory eﬀect of the auxiliary
subunit was partially lost (N136Q, )451 83 pA; N184Q,
)439 94 pA). Both mutants prevented equally the CaVa2d-
mediated regulation of Cav channels. Interestingly, it was
found that the evident current stimulation observed in wild-
type transfected cells was absent in the cells expressing the
CaVa2d-1 subunit harboring the double mutation (DM,
)242 49 pA; a2d, )198 67 pA). These data are further
illustrated in Fig. 3A, which shows the IBa density (current
amplitudes divided by the respective values of Cm) as a func-
tion of the voltage step in cells transfected with the wild-type
CaVa2d-1 and its mutations. These current density–voltage
relationships indicate that IBa is activated at potentials positive
to )20 mV and reach its peak at potentials close to +10 mV.
Notably, the eﬀects of the CaVa2d-1 mutant subunits were
observed at almost all potentials explored.
We next investigated whether the eﬀects of the mutations
could be explained by alterations in the macroscopic kinetic
properties. Normalized currents obtained from either control
Fig. 1. Mutation of two NX(S/T) motifs to delete extracellular N -linked glycosylation sites in the CaVa2d subunit. (A) Schematic representation of
the CaVa2d-1 subunit. SS denotes signal sequence, H1 and H2 indicate hydrophobic regions; the protein is represented as a horizontal rectangle, and
 indicates the cleavage site between the a2 and d peptides. TM denotes the transmembrane domain in d. Arrows indicate the positions of the two
asparagine residues (N136 and N184) in the 28–184 stretch accessible for glycosylation. (B) Agarose gel analysis of the cDNA constructs coding the
full-length CaVa2d-1 (pIRES/a2d) and its N -glycosylation mutants (pIRES/N136Q, pIRES/N184Q and the double mutation pIRES/DM). Re-
striction analysis showed the expected 5.4 and 3.5 Kb fragments corresponding to the pIRES-hrGFP-1a vector and the CaVa2d-1 inserts (wild-
type and mutants). (C) Western blot analysis of membranes from mock transfected HEK-293 cells (pIRES) or cells expressing the wild-type (pIRES/
a2d), and the N -glycosylation mutants of the CaVa2d-1 subunit (pIRES/N136Q, pIRES/N184Q and pIRES/DM).
Fig. 2. Mutations at sites N136 and N184 in the extracellular a2 domain disrupt the function of CaVa2d-1. (A) Superimposed representative whole-
cell Ba2þ current traces through recombinant CaV channels (CaV2.2/b3) in HEK-293 cells expressing wild-type (control) and N -glycosylation mutants
of the a2d-1 subunit (N136Q, N184Q and DM). Currents were generated by applying 140 ms activating pulses at +10 mV from a HP of )80 mV. (B)
Summary histograms showing the average peak current from control and cells expressing the CaVa2d-1 N -glycosylation mutants. The open bar shows
the average current amplitude in the absence of the a2d subunit. The number of recorded cells is indicated in parentheses, and the asterisks denote
signiﬁcant diﬀerences (P < 0:05).
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temporal course of the current traces was very similar, sug-
gesting that the activation and inactivation rate of the channels
was not altered (data not shown). Accordingly, neither the
time to peak nor the time constant for the activation of the
current (sact) were signiﬁcantly modiﬁed (Fig. 3B; Table 1).
Likewise, we generated complete voltage-dependent inactiva-
tion curves for the recombinant CaV channels expressed. Ex-
cept for the marked reduction in the maximal current
amplitude observed when the mutant subunits were present
(2-fold; N136Q and N184Q, and 4-fold for DM; see
Fig. 2B), the other Boltzmann parameters describing the in-
activation curves (i.e. V1=2 and k) were virtually the same to the
corresponding values obtained from cells expressing wild-typeCaVa2d-1 (Fig. 4A; Table 1). Lastly, the time constant for the
inactivation of the current (sinact) and the percentage of current
remaining after 140 ms activating pulses were practically in-
distinguishable between control and cells expressing the mu-
tant subunits (Fig. 4B; Table 1). Thus, alterations in the
activation and/or inactivation properties of the channels may
not be contributing to the observed reductions in the magni-
tude of the whole-cell currents.4. Discussion
To uncover potential molecular determinants for the
CaVa2d subunit-mediated up-regulation of Ca2þ channels, in
Table 1
Whole-cell current parameters in HEK-293 cells transfected with CaV2.2/b3 and the wild-type or the N -linked glycosylation mutants of the a2d-1
auxiliary subunit
a2d-1 construct Activation Inactivation
Time to peak (ms)a s (ms)a s (ms)a I remaining (%)a V1=2 (mV) k (mV)
WT 8.1 0.2 2.1 0.1 69.5 3.8 21.6 1.5 )51.0 )11.1
N136Q 8.8 0.4 2.3 0.1 68.7 4.0 23.8 1.9 )51.6 )13.5
N184Q 7.5 0.4 2.2 0.2 63.4 6.9 20.0 2.9 )54.5 )11.8
DM 9.2 0.7 2.7 0.4 77.8 16.2 22.7 2.7 )52.3 )13.5
a2d 9.4 0.7 2.2 0.2 113.0 31.7 36.6 5.7 )51.2 )13.5
Each value is meanS.E.M.
WT: wild-type; DM: double mutation.
a Currents were recorded during depolarizations from )80 to +10 mV.
Fig. 4. Glycosylation at sites N136 and N184 of CaVa2d-1 does not aﬀect Ca2þ channel inactivation. (A) Normalized, averaged steady-state inac-
tivation curves for CaV2.2/b3 recombinant channels co-expressing wild-type (control) and the N -glycosylation mutants. Symbols denote average
S.E.M. of the normalized data at a given membrane potential for 7–18 diﬀerent cells. Solid lines represent single Boltzmann ﬁts to the averaged
data. (B) Average time constants of inactivation (sinact) and percentage of current remaining 140 ms into the depolarizing pulse in cells expressing the
wild-type (control) and N -glycosylation mutants of CaVa2d-1. The values of sinact were obtained by ﬁtting the decaying phase of the currents with an
exponential function (see Section 2). Average S.E.M. from 9 to 35 recorded cells in each group is shown.
Fig. 3. Glycosylation at sites N136 and N184 of CaVa2d-1 inﬂuences Ca2þ channel functional expression without aﬀecting activation. (A) Current–
voltage relationship for cells transfected with CaV2.2/b3 and wild-type (control) and N -glycosylation mutants of a2d-1: N136Q (black squares) or
N184Q (grey circles) or the double mutation, DM (white circles). Data points represent the average current densityS.E.M. at a test potential as
listed, from 6 to 15 cells recorded in each group. (B) Average IBa time to peak and time constants (sact) for the activation of the recombinant CaV
channels. The values of sact were estimated by ﬁtting the rising phase of the current traces with an exponential function (see Section 2). Average
S.E.M. from 10 to 45 cells in each group is shown.
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glycosylation sites (N136 and N184) located at the extra-
cellular a2 domain of the protein. Our ﬁndings show that
CaVa2d-1 heterologously expressed in the HEK-293 cells
could be glycosylated in sites N136 and N184, and by mu-
tagenesis of both residues we were able to create non-func-tional CaVa2d-1 glycosylated deﬁcient variants. Consistent
with the notion that the N -glycosylation of the CaVa2d-1
subunit is responsible for an important stimulation of
channel activity [16], co-expression of wild-type CaVa2d-1
with CaV2.2 and CaVb3 subunits resulted in a 4-fold increase
in whole-cell Ca2þ current amplitude. To determine whether
A. Sandoval et al. / FEBS Letters 576 (2004) 21–26 25both or only one glycosylation site on CaVa2d needs to be
glycosylated to increase current amplitude, we tested single
glycosylation mutants. When either the N136Q or the
N184Q mutant was co-expressed with CaV2.2/CaVb3 chan-
nels, the current was reduced to 56% of control. These
results indicate that both N -glycosylation sites are critical for
the CaVa2d-mediated regulation of Ca2þ channels. In addi-
tion, when the double glycosylation mutant was co-trans-
fected, the current was further reduced (to 31% of
control). Interestingly, the average current amplitude in the
presence of the DM of glycosylation was very similar to the
magnitude of the currents in the absence of the a2d subunit
(Fig. 2B). However, the waveforms in the two conditions
were diﬀerent. Currents in the absence of any a2d subunits
inactivate signiﬁcantly slower (see s of inactivation and I
remaining in Table 1), suggesting that all the abnormally
glycosylated proteins, including the DM still interact with
the channel.
Taken as a whole, our data suggest that the less glycosylated
CaVa2d-1 subunits are ineﬃcient in traﬃcking to the cell
membrane or are less stable once they reach the membrane
[16]. In keeping with this view, the functional properties of the
channels were practically unaltered (Figs. 3B and 4) and only
major alterations were observed in the maximal conductance
which depends on the number of functional channels. Thus,
conceivable alterations in the number of CaV channels at the
plasma membrane might be accounting for the eﬀects of the
CaVa2d-1 N -glycosylation mutants.
Indeed, glycosylation of some ion channels has been shown
to inﬂuence their membrane targeting and surface expression
[42–44]. In particular, a number of Kþ channel types are gly-
cosylated on asparagine residues and mutation of these resi-
dues indicates that glycosylation may drastically increase the
stability and cell surface expression of the channel proteins
[44–48]. It is well known that in the absence of N-linked gly-
cosylation, protein may be retained in the endoplasmic retic-
ulum (ER) and degraded [45,47]. Interestingly, in HEK-293
cells, glycosylation stabilizes the Shaker Kþ channel and
drastically enhances its traﬃcking to the cell surface probably
by an interaction with calnexin and/or calreticulin which
protects newly made Shaker proteins from retrotranslocation
and degradation [49,50]. However, interactions between the
CaVa2d-1 auxiliary subunit and the ER resident proteins have
not been documented yet. Alternatively, the wild-type and
unglycosylated CaVa2d-1 proteins may be diﬀerentially sensi-
tive to ER-associated retention because are transported out of
the ER at diﬀerent rates. In this scenario, glycosylation may
increase the rate of folding and assembly of the CaVa2d-1
protein, thereby allowing a more rapid exit from the ER. Exit
on time from the ER may be a key factor in preventing the
wild-type CaVa2d-1 but not the unglycosylated mutant
proteins from retention. Hence, retention of CaVa2d-1 glyco-
sylation mutants in the ER, and the kinetics of ER exit of the
wild-type and unglycosylated a2d proteins are interesting
topics for future studies.
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